Axiron is a brand of testosterone replacement therapy (TRT) manufactured by Eli Lilly. According to Lilly's website, Axiron is the "only underarm low testosterone (lot T) treatment" and is "clinically proven to restore T levels to the normal range in most men."
Available package inserts recommend a starting dose for Axiron at 60 mg (2 pump actuations) applied topically once daily. In addition to starting dosages, historical AndroGel package inserts have warned patients about increased risks for, e.g., prostate cancer, increased hematocrit, spermatogenesis, hepatic impairment, edema, gynecomastia, sleep apnea, and hypercalcemia. However, little if any information has been disclosed about a potential increase in risk for:
Following the FDA Safety Alert released in January of 2014, Bottar Leone, PLLC began investigating Axiron labeling, including whether patients were sufficiently aware of statistically significant risks associated with use of the medication. If Lilly knew or should have known of the risks and did not disclose all-together, or provided an inadequate warning to physicians and consumers on bottles and package inserts, it may be liable for damages, including compensation for:
To speak with a member of our legal team to learn more about whether your use of AndroGel, Androderm, Axiron, Androud 10, Depo-Testosterone, Bio-T-Gel, Delatestryl, Fortesta, Straint, Testin or Testopel caused a cardiac or embolic event, contact us at (800) 336-5297, or by email at email@example.com.